Literature DB >> 7094925

Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia.

M Fischer, W Vetter, B Winterg, W Zidek, H Vetter.   

Abstract

In primary aldosteronism the type of adrenal lesion was correctly identified in 28 of 40 patients (70%) by standard adrenal scintigraphy. Suppression scintigraphy did not improve the validity of the method. In all patients the diagnosis was confirmed by surgery (unilateral adenoma n = 32; bilateral adrenal hyperplasia n = 11). False classification of the adrenal lesion(s) by standard scintigraphy was mostly due to a bilateral adrenal isotopic uptake in patients with an unilateral aldosteronoma. However, a substantial number of these patients (6 of 11 patients) received long-term spironolactone treatment prior to the examination. Thus, in primary aldosteronism adrenal changes induced by chronic spironolactone administration are probably a major cause for incorrect differentiation between adenoma and hyperplasia by adrenal scintigraphy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094925     DOI: 10.1007/BF00256468

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.

Authors:  H Vetter; W Vetter
Journal:  Klin Wochenschr       Date:  1975-04-15

2.  Primary aldosteronism: diagnosis, localization, and treatment.

Authors:  M H Weinberger; C E Grim; J W Hollifield; D C Kem; A Ganguly; N J Kramer; H Y Yune; H Wellman; J P Donohue
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

3.  Effect of a spirolactone on plasma and urinary aldosterone in primary aldosteronism.

Authors:  H Vetter; M Appenheimer; R Lucas; H Weiand; M L Herschbach; K Glänzer; F Witassek; F Krück
Journal:  Horm Res       Date:  1977

4.  Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies.

Authors:  J W Conn; D L Hinerman
Journal:  Metabolism       Date:  1977-12       Impact factor: 8.694

5.  Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case.

Authors:  J A Sundsfjord; P Marton; H Jorgensen; A Aakvaag
Journal:  J Clin Endocrinol Metab       Date:  1974-10       Impact factor: 5.958

6.  131 I-19-iodocholesterol in the diagnosis of adrenal disease.

Authors:  W H Beierwaltes; L M Lieberman; A N Ansari; H Nishiyama
Journal:  J Lab Clin Med       Date:  1971-12

7.  Effect of spironolactone on aldosterone regulation in man.

Authors:  R C Gaillard; A M Riondel; P Chabert; M B Vallotton
Journal:  Clin Sci (Lond)       Date:  1980-03       Impact factor: 6.124

8.  Lateralization procedures in primary aldosteronism.

Authors:  H Vetter; G Brecht; M Fischer; M Galanski; K Glänzer; B M Cramer; G Pouliadis; G Sialer; A Studer; W Tenschert; S Wollnik; H Zumkley; W Vetter
Journal:  Klin Wochenschr       Date:  1980-10-15

9.  Fine structure and morphogenesis of spironolactone bodies in the zona glomerulosa of the human adrenal cortex.

Authors:  K Kovacs; E Horvath; W Singer
Journal:  J Clin Pathol       Date:  1973-12       Impact factor: 3.411

Review 10.  Effects in animals of chronic administration of spironolactone--a review.

Authors:  G Lumb; P Newberne; J H Rust; B Wagner
Journal:  J Environ Pathol Toxicol       Date:  1978 May-Jun
  10 in total
  1 in total

Review 1.  Drug interactions with radiopharmaceuticals.

Authors:  S Hesslewood; E Leung
Journal:  Eur J Nucl Med       Date:  1994-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.